HSP90AA1 and posterior cortical atrophy: One of the first-generation inhibitors targeting the N-terminal domain of HSP90 is tanespimycin (17-N-Allylamino-17 demethoxygeldanamycin, 17-AAG) which enhanced the degradation of AR in PCa cell lines and in mouse xenograft models [123].